In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Moderna and Merck team up again, this time in oncology

Executive Summary

Building on a successful partnership that began last year, Moderna Therapeutics LLC and Merck & Co. Inc. joined forces again, this time to develop mRNA-based personalized cancer vaccines that could be complementary to Merck's anti-PD-1 antibody therapy Keytruda.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies